Kaufman and Ruhoy and their free Unraveled series
Interestingly, no difference in food intake was observed between wild-type mice treated with the dual incretin GLP-1/GIP coagonist and those treated with the tri-agonist despite the difference in weight loss, and this was found to be due to significantly higher ATP expenditure in tri-agonist-treated diet-induced obese mice
In 1990 Mojsov and colleagues also described the existence of a second biologically active form of GLP-1, labelled GLP-1 (7-36) amide, in the intestines (Mojsov, Kopczynski, Habener)
That is only 48 hours
June 2026 update: FDA issues 25 more warning letters to telehealth companies During the week of June 15, 2026 - days before this article was published - the FDA issued 25 additional warning letters to telehealth companies over false or misleading promotional claims about compounded GLP-1 products
[14] [15] These increases were observed early in treatment and generally persisted throughout the trial periods